144 related articles for article (PubMed ID: 37962587)
1. Empagliflozin ameliorates liver fibrosis in NASH rat model via targeting hepatic NF-κB/SOX9/OPN signaling and osteocalcin level.
Elseweidy MM; Ali AE; Hassanin SM; Mahmoud YK
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3449-3459. PubMed ID: 37962587
[TBL] [Abstract][Full Text] [Related]
2. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation.
Afrin R; Arumugam S; Rahman A; Wahed MI; Karuppagounder V; Harima M; Suzuki H; Miyashita S; Suzuki K; Yoneyama H; Ueno K; Watanabe K
Int Immunopharmacol; 2017 Mar; 44():174-182. PubMed ID: 28110063
[TBL] [Abstract][Full Text] [Related]
3. Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf-κB Pathway.
Ou Q; Weng Y; Wang S; Zhao Y; Zhang F; Zhou J; Wu X
Dig Dis Sci; 2018 Dec; 63(12):3398-3408. PubMed ID: 30191499
[TBL] [Abstract][Full Text] [Related]
4. The modulation of hepatic adenosine triphosphate and inflammation by eicosapentaenoic acid during severe fibrotic progression in the SHRSP5/Dmcr rat model.
Jia X; Naito H; Yetti H; Tamada H; Kitamori K; Hayashi Y; Yamagishi N; Wang D; Yanagiba Y; Ito Y; Wang J; Tanaka N; Ikeda K; Yamori Y; Nakajima T
Life Sci; 2012 Jun; 90(23-24):934-43. PubMed ID: 22569299
[TBL] [Abstract][Full Text] [Related]
5. Anti-toll-like receptor 2 antibody ameliorates hepatic injury, inflammation, fibrosis and steatosis in obesity-related metabolic disorder rats via regulating MAPK and NF-κB pathways.
Wu L; Sun J; Liu L; Du X; Liu Y; Yan X; Kombo Osoro E; Zhang F; Feng L; Liang D; Li Y; Chen Q; Sun S; Zhang L; Lan X; Li D; Lu S
Int Immunopharmacol; 2020 Mar; 82():106368. PubMed ID: 32151955
[TBL] [Abstract][Full Text] [Related]
6. Pyrvinium pamoate attenuates non-alcoholic steatohepatitis: Insight on hedgehog/Gli and Wnt/β-catenin signaling crosstalk.
El-Derany MO; El-Demerdash E
Biochem Pharmacol; 2020 Jul; 177():113942. PubMed ID: 32240652
[TBL] [Abstract][Full Text] [Related]
7.
Wang F; Liu S; Zhuang R; Bao J; Shen Y; Xi J; Sun J; Fang H
Int J Clin Exp Pathol; 2018; 11(11):5351-5358. PubMed ID: 31949616
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin Ameliorates Progression From Prediabetes to Diabetes and Improves Hepatic Lipid Metabolism: A Systematic Review.
Hossain MF; Khan NA; Rahman A; Chowdhury MFI; Bari S; Khan MA; Masud UW; Zakia UB; Paul SP; Tasnim N
Cureus; 2022 Aug; 14(8):e28367. PubMed ID: 36168335
[TBL] [Abstract][Full Text] [Related]
9. Lactoferrin Prevents Hepatic Injury and Fibrosis via the Inhibition of NF-κB Signaling in a Rat Non-Alcoholic Steatohepatitis Model.
Aoyama Y; Naiki-Ito A; Xiaochen K; Komura M; Kato H; Nagayasu Y; Inaguma S; Tsuda H; Tomita M; Matsuo Y; Takiguchi S; Takahashi S
Nutrients; 2021 Dec; 14(1):. PubMed ID: 35010924
[TBL] [Abstract][Full Text] [Related]
10. Eugenol modulates insulin sensitivity by upregulating insulin receptor substrate-2 in non-alcoholic fatty liver disease in rats.
Fawzy MH; Saeed NM; El-Sherbiny DA; El-Demerdash E
J Pharm Pharmacol; 2021 Apr; 73(6):846-854. PubMed ID: 33822104
[TBL] [Abstract][Full Text] [Related]
11. Renoprotective effect of empagliflozin in cafeteria diet-induced insulin resistance in rats: Modulation of HMGB-1/TLR-4/NF-κB axis.
Al-Wakeel DE; El-Kashef DH; Nader MA
Life Sci; 2022 Jul; 301():120633. PubMed ID: 35568226
[TBL] [Abstract][Full Text] [Related]
12. A novel model of non-alcoholic steatohepatitis with fibrosis and carcinogenesis in connexin 32 dominant-negative transgenic rats.
Naiki-Ito A; Kato H; Naiki T; Yeewa R; Aoyama Y; Nagayasu Y; Suzuki S; Inaguma S; Takahashi S
Arch Toxicol; 2020 Dec; 94(12):4085-4097. PubMed ID: 32833043
[TBL] [Abstract][Full Text] [Related]
13. A novel combination therapy targets sonic hedgehog signaling by the dual inhibition of HMG-CoA reductase and HSP90 in rats with non-alcoholic steatohepatitis.
Mohammed OA; Youssef ME; Doghish AS; Hamad RS; Abdel-Reheim MA; Alghamdi M; Alamri MMS; Alfaifi J; Adam MIE; Alharthi MH; Alhalafi AH; Bahashwan E; Rezigalla AA; BinAfif DF; Abdel-Ghany S; Attia MA; Elmorsy EA; Al-Noshokaty TM; Fikry H; Saleh LA; Saber S
Eur J Pharm Sci; 2024 Jul; 198():106792. PubMed ID: 38714237
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tumor necrosis factor-α enhanced the antifibrotic effect of empagliflozin in an animal model with renal insulin resistance.
Mohamed HE; Asker ME; Keshawy MM; Hasan RA; Mahmoud YK
Mol Cell Biochem; 2020 Mar; 466(1-2):45-54. PubMed ID: 31933108
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte-specific loss of LAP2α protects against diet-induced hepatic steatosis, steatohepatitis, and fibrosis in male mice.
Upadhyay KK; Choi EK; Foisner R; Omary MB; Brady GF
Am J Physiol Gastrointest Liver Physiol; 2023 Aug; 325(2):G184-G195. PubMed ID: 37366543
[TBL] [Abstract][Full Text] [Related]
16. The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression.
Schulien I; Hockenjos B; Schmitt-Graeff A; Perdekamp MG; Follo M; Thimme R; Hasselblatt P
Cell Death Differ; 2019 Sep; 26(9):1688-1699. PubMed ID: 30778201
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis.
Coombes JD; Choi SS; Swiderska-Syn M; Manka P; Reid DT; Palma E; Briones-Orta MA; Xie G; Younis R; Kitamura N; Della Peruta M; Bitencourt S; Dollé L; Oo YH; Mi Z; Kuo PC; Williams R; Chokshi S; Canbay A; Claridge LC; Eksteen B; Diehl AM; Syn WK
Biochim Biophys Acta; 2016 Jan; 1862(1):135-44. PubMed ID: 26529285
[TBL] [Abstract][Full Text] [Related]
18. Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis.
Hassan NF; Nada SA; Hassan A; El-Ansary MR; Al-Shorbagy MY; Abdelsalam RM
Inflammation; 2019 Jun; 42(3):1056-1070. PubMed ID: 30737662
[TBL] [Abstract][Full Text] [Related]
19. [Establishment of a complex alcoholic liver fibrosis mouse model and investigation of OPN and TGF-beta1 hepatic expression].
Kong LB; Ren WG; Mi HM; Zhao SX; Zhang YG; Nan YM
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):207-12. PubMed ID: 23967743
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-κB-TNFα pathway.
Zhang T; Hu J; Wang X; Zhao X; Li Z; Niu J; Steer CJ; Zheng G; Song G
J Hepatol; 2019 Jan; 70(1):87-96. PubMed ID: 30218679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
